Better Sleep Through Screen Time: The Role of Telehealth in Sleep Care for the School-Aged Child

Background Sleep plays an integral role in a child’s physical and neuropsychological development. Children with sleep disorders are at risk of developing inattention, hyperactivity, and learning difficulties, challenges that impact them, their families, their classmates, and their communities.26 There is a paucity of pediatric sleep medicine providers equipped to partner with families in identifying and addressing sleep disorders. Additional barriers to accessing this specialized care include geographic proximity, parental ability to take time off from work, and hesitance for a child to miss valuable learning time at school. During the SARS-CoV-2 pandemic, our pediatric sleep department transitioned from largely in-person care to a predominantly virtual platform and collected data to monitor the impact of this transition. In this study, we share several key trends that emerged which may have broad implications on how pediatric sleep medicine providers can better support school-aged children with sleep challenges. Methods We performed a chart review of all scheduled pediatric sleep medicine visits from June 2019 to June 2021, a time frame that included the pandemic-driven overnight transition from in-person to virtual clinic visits. The STEM framework1 was developed by pediatric telehealth experts to provide a unified approach to assessing the impact of telehealth programs. We applied this framework to the collected data to gauge the impact on the four major domains highlighted in STEM: health outcomes, healthcare delivery, individual experience (patient and provider), and program implementation. Results The data demonstrated an increased proportion of completed visits and a decreased proportion of canceled/no-show visits when care was provided virtually. Patients accessing virtual care were doing so from greater distances than those who had in-person visits. The school-aged (5-12 years) cohort utilizing telehealth had notable differences in past medical history, with significantly more Attention Deficit-Hyperactivity Disorder. They also presented with significantly more insomnia and behavioral sleep difficulties. Discussion Sleep disorders are common, and school-aged children have much to gain from sleep optimization. However, pediatric sleep care can be challenging to access. Geographic distance and time away from school and work preclude many families from formal sleep consultations. Telehealth allows high-quality pediatric sleep care to be offered in an easily accessible format to those near and far, resulting in clinics running more efficiently and school-aged children, who need it most, to receive the tools they need to sleep soundly. With a convenient click, families are better able to fit virtual sleep consultations into their day, without the stress of travel or the waiting room. They complete more scheduled visits, allowing pediatric sleep medicine departments to deliver care more efficiently. The low-pressure virtual platform also permits families to seek care for behavioral sleep issues. While our department’s transition to predominantly virtual care occurred amidst a pandemic, with many confounding factors limiting the interpretation of the data we collected, the trends seen are very promising. Key Take Away Points Pediatric sleep medicine consultation is a highly needed but scarce resource. Pediatric sleep medicine clinics can run more efficiently when utilizing telehealth. School-aged children with ADHD or suffering from insomnia may access sleep care at greater rates when care is offered virtually.

SARS-CoV-2 in a tropical area of Colombia, a remarkable conversion of presymptomatic to symptomatic people impacts public health.

BACKGROUND: The ability of SARS-CoV-2 to remain in asymptomatic individuals facilitates its dissemination and makes its control difficult. OBJECTIVE: To establish a cohort of asymptomatic individuals, change to the symptomatic status, and determine the most frequent clinical manifestations.  METHODS: Between April 9 and August 9, 2020, molecular diagnosis of SARS-CoV-2 infection was confirmed in 154 asymptomatic people in contact with subjects diagnosed with COVID-19. Nasopharyngeal swabs were performed on these people in different hospitals in Córdoba, the Caribbean area of Colombia. The genes E, RdRp, and N were amplified with RT-qPCR. Based on the molecular results and the Cq values, the patients were subsequently followed up through telephone calls to verify their health conditions. RESULTS: Overall, of 154 asymptomatic individuals, 103 (66.9%) remained asymptomatic, and 51 (33.1%) changed to symptomatic. The most frequent clinical manifestations in young people were anosmia and arthralgia. Adults showed cough, ageusia, and odynophagia; in the elderly were epigastralgia, dyspnea, and headache. Mortality was 8%. CONCLUSIONS: A proportion of 33% of presymptomatic individuals was found, of which four of them died. This high rate could indicate a silent transmission, contributing significantly to the epidemic associated with SARS-CoV-2.

Factors Determining Plasticity of Responses to Drugs.

The plasticity of responses to drugs is an ever-present confounding factor for all aspects of pharmacology, influencing drug discovery and development, clinical use and the expectations of the patient. As an introduction to this Special Issue of the journal IJMS on pharmacological plasticity, we address the various levels at which plasticity appears and how such variability can be controlled, describing the ways in which drug responses can be affected with examples. The various levels include the molecular structures of drugs and their receptors, expression of genes for drug receptors and enzymes involved in metabolism, plasticity of cells targeted by drugs, tissues and clinical variables affected by whole body processes, changes in geography and the environment, and the influence of time and duration of changes. The article provides a rarely considered bird's eye view of the problem and is intended to emphasize the need for increased awareness of pharmacological plasticity and to encourage further debate.

The effect of known and unknown confounders on the relationship between air pollution and Covid-19 mortality in Italy: A sensitivity analysis of an ecological study based on the E-value.

Back in December 2019, the novel coronavirus disease 2019 (Covid-19) started rapidly spreading worldwide, especially in Italy that was among the most affected countries. The geographical distribution of air pollution and Covid-19 mortality in Italy suggested atmospheric pollution as a worsening factor of severe Covid-19 health outcomes. The present nationwide ecological study focused on all 107 Italian territorial areas, aiming to assess the potential association between Particulate Matter concentration, less than 2.5 µm in diameter (exposure), and Covid-19 mortality rate (outcome) throughout 2020, by looking at 28 potential confounders. A potential positive association between exposure and outcome was observed when performing a multivariate regression analysis with a Negative Binomial model, suggesting that an increase of 1 µg/m3 in the exposure is associated with an increase of 9.0% (95% CI: 6.5%-11.6%) in the average Covid-19 mortality rate, conditional on all 28 potential confounders. A sensitivity analysis, based on the E-value, shows that a hypothetical unmeasured confounder would have to be associated with both PM2.5 concentration and Covid-19 mortality rate by a rate ratio of at least 1.40-fold each to explain away the exposure-outcome association, conditional on all 28 covariates included in the main analysis model. Moreover, the Observed Covariate E-value (OCE) was reported to provide a contextualization of the E-value on the observed covariates included in the study. The OCE sensitivity analysis shows that a set of unknown confounders similar in size and magnitude to the set of the considered climatic factors could potentially explain away the estimated exposure-outcome association. Consequently, the role of climatic factors in the Covid-19 pandemic is worth of further investigation.

Exploring spatiotemporal effects of the driving factors on COVID-19 incidences in the contiguous United States.

Since December 2019, the world has witnessed the stringent effect of an unprecedented global pandemic, coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As of January 29,2021, there have been 100,819,363 confirmed cases and 2,176,159 deaths reported. Among the countries affected severely by COVID-19, the United States tops the list. Research has been conducted to discuss the causal associations between explanatory factors and COVID-19 transmission in the contiguous United States. However, most of these studies focus more on spatial associations of the estimated parameters, yet exploring the time-varying dimension in spatial econometric modeling appears to be utmost essential. This research adopts various relevant approaches to explore the potential effects of driving factors on COVID-19 counts in the contiguous United States. A total of three global spatial regression models and two local spatial regression models, the latter including geographically weighted regression (GWR) and multiscale GWR (MGWR), are performed at the county scale to take into account the scale effects. For COVID-19 cases, ethnicity, crime, and income factors are found to be the strongest covariates and explain most of the variance of the modeling estimation. For COVID-19 deaths, migration (domestic and international) and income factors play a critical role in explaining spatial differences of COVID-19 deaths across counties. Such associations also exhibit temporal variations from March to July, as supported by better performance of MGWR than GWR. Both global and local associations among the parameters vary highly over space and change across time. Therefore, time dimension should be paid more attention to in the spatial epidemiological analysis. Among the two local spatial regression models, MGWR performs more accurately, as it has slightly higher Adj. R2 values (for cases, R2 = 0.961; for deaths, R2 = 0.962), compared to GWR's Adj. R2 values (for cases, R2 = 0.954; for deaths, R2 = 0.954). To inform policy-makers at the nation and state levels, understanding the place-based characteristics of the explanatory forces and related spatial patterns of the driving factors is of paramount importance. Since it is not the first time humans are facing public health emergency, the findings of the present research on COVID-19 therefore can be used as a reference for policy designing and effective decision making.

COVID-19: The Ivermectin African Enigma.

INTRODUCTION: The low frequency of cases and deaths from the SARS-CoV-2 COVID-19 virus in some countries of Africa has called our attention about the unusual behavior of this disease. The ivermectin is considered a drug of choice for various parasitic and viral diseases and shown to have in vitro effects against SARS-CoV-2. AIMS: Our study aimed to describe SARS-CoV2 infection and death rates in African countries that participated in an intensive Ivermectin mass campaign carried out to control onchocerciasis and compare them with those of countries that did not participate. METHODS: Data from 19 countries that participated in the World Health Organization (WHO) sponsored African Programme for Onchocerciasis Control (APOC), from 1995 until 2015, were compared with thirty-five (Non-APOC), countries that were not included. Information was obtained from https://www.worldometers.info/coronavirus/ database. Generalized Poisson regression models were used to obtain estimates of the effect of APOC status on cumulative SARS-CoV-2 infection and mortality rates. RESULTS: After controlling for different factors, including the Human Development Index (HDI), APOC countries (vs. non-APOC), show 28% lower mortality (0.72; 95% CI: 0.67-0.78) and 8% lower rate of infection (0.92; 95% CI: 0.91-0.93) due to COVID-19. CONCLUSIONS: The incidence in mortality rates and number of cases is significantly lower among the APOC countries compared to non-APOC countries. That a mass public health preventive campaign against COVID-19 may have taken place, inadvertently, in some African countries with massive community ivermectin use is an attractive hypothesis. Additional studies are needed to confirm it.

INTRODUCCIÓN: La baja frecuencia de casos y muertes por el virus SARS-CoV-2 COVID-19 en algunos países de África llamó nuestra atención sobre el comportamiento inusual de esta enfermedad. La ivermectina se considera un fármaco de elección para diversas enfermedades parasitarias y virales, y se ha demostrado que tiene efectos in vitro contra el SARS-CoV-2. OBJETIVOS: Nuestro estudio tiene el objetivo describir las tasas de infección y mortalidad del SARS-CoV-2 en los países africanos que participaron en una campaña intensiva masiva de ivermectina para el control de la oncocercosis y compararlas con las de los países que no participaron. MÉTODOS: Los datos de 19 países que participaron en el Programa Africano para el Control de la Oncocercosis (APOC) patrocinado por la Organización Mundial de la Salud (OMS), desde 1995 hasta 2015, se compararon con 35 países que no fueron incluidos (NO APOC). La información sobre casos y muertes por COVID-19 se obtuvo de la base de datos https://www.worldometers.info/coronavirus/. Se utilizaron modelos de regresión de Poisson para obtener estimaciones del efecto del estado APOC sobre las tasas acumuladas de infección y mortalidad por SARS-CoV-2. RESULTADOS: Después de controlar diferentes factores, incluido el Índice de Desarrollo Humano (IDH), los países APOC (frente a los no APOC) mostraron una mortalidad 28% menor (razón de tasas ajustada: RR= 0.72, IC 95%: 0.67-0.78) y una tasa de infección 8% menor (RR= 0.92, IC 95%: 0.91-0.93) por COVID-19. CONCLUSIONES: Las tasas de mortalidad e infección son significativamente más bajas en países APOC en comparación con los países no APOC. Una campaña preventiva masiva de salud pública contra el COVID-19 pudo haber tenido lugar inadvertidamente en algunos países africanos con un uso masivo de ivermectina en la comunidad es una hipótesis atractiva. Se necesitan estudios adicionales para confirmarlo.